We are proud to announce our largest round of rare cancer grant funding to date: $200,000 in new grants supporting innovative rare cancer research, as well as a new program supporting patients facing cholangiocarcinoma. Learn more about each of these exciting new grants and programs below.
$125,000 supporting cholangiocarcinoma research at the Bardeesy Lab at the Massachusetts General Hospital Cancer Center, marking our 6th year of support for Nabeel Bardeesy with total funding of over $500,000.
The comprehensive cholangiocarcinoma research program built through our ongoing partnership is advancing the field of research for this disease. This new grant builds on our prior support, and funds pioneering studies into the role of the IDH mutation and and FGFR2 gene alteration. Our funding also expands research around a cholangiocarcinoma clinical trial sponsored by TargetCancer Foundation, which is currently enrolling patients at MGH.
In addition, our new Patient Assistance Fund provides direct funding to patients from around the country who are enrolling in the clinical trial mentioned above. This fund provides patients with reimbursement for the overwhelming expenses incurred when participating in the trial.
$75,000 supporting esophageal cancer research at the Bass Lab at the Dana-Farber Cancer Institute, marking five years and over $235,000 inesophageal cancer research funding.
Our prior support helped to uncover new immunotherapeutic targets, leading to a clinical trial opening this year. This new funding will empower Dr. Adam Bass to conduct in depth studies into each patient in the trial. This will allow for a better understanding of why some patients respond to immunotherapy, and just as importantly, why others do not.
These projects are only possible through the continued generosity of so many people who support us throughout the year. Your contributions truly make a difference, and we are excited to keep you updated on the progress of this critical work.